Synthesis and characterization of some new Cu(II), Ni(II) and Zn(II) complexes with salicylidene thiosemicarbazones: Antibacterial, antifungal and in vitro antileukemia activity

Pakhontsu E.; Fala Valeriu; Gulya Aurelian; Poirier Donald; Tsapkov Victor I.; Roshu T.

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

120

Ultima descărcare din IBN:
2023-10-26 11:58

SM ISO690:2012

PAKHONTSU, E., FALA, Valeriu, GULYA, Aurelian, POIRIER, Donald, TSAPKOV, Victor I., ROSHU, T.. Synthesis and characterization of some new Cu(II), Ni(II) and Zn(II) complexes with salicylidene thiosemicarbazones: Antibacterial, antifungal and in vitro antileukemia activity. In: Molecules (Basel, Switzerland), 2013, vol. 18, pp. 8812-8836. ISSN -. DOI: https://doi.org/10.3390/molecules18088812

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

Molecules (Basel, Switzerland)

Volumul 18 / 2013 / ISSN - /ISSNe 1420-3049

Synthesis and characterization of some new Cu(II), Ni(II) and Zn(II) complexes with salicylidene thiosemicarbazones: Antibacterial, antifungal and in vitro antileukemia activity

DOI:https://doi.org/10.3390/molecules18088812

Pag. 8812-8836

Pakhontsu E.¹, Fala Valeriu², Gulya Aurelian³, Poirier Donald⁴, Tsapkov Victor I.³, Roshu T.⁵

¹ University of Medicine and Pharmacy “Carol Davilla”, Bucharest,
² ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
³ Moldova State University,
⁴ CHUL Research Center (Université Laval),
⁵ University of Bucharest

Proiecte:

Menționat în lucrare: FQRNT Nr.115825 Synthèse et caractérisation de nouveaux complexes métal-stéroïde comme agents anticancéreux

Disponibil în IBN: 18 septembrie 2023

Descarcă PDF

Rezumat

Thirty two new Cu(II), Ni(II) and Zn(II) complexes (1-32) with salicylidene thiosemicarbazones (H₂L¹-H₂L¹⁰) were synthesized. Salicylidene thiosemicarbazones, of general formula (X)N-NH-C(S)-NH(Y), were prepared through the condensation reaction of 2-hydroxybenzaldehyde and its derivatives (X) with thiosemicarbazide or 4-phenylthiosemicarbazide (Y = H, C₆H₅). The characterization of the new formed compounds was done by ¹H-NMR, ¹³C-NMR, IR spectroscopy, elemental analysis, magnetochemical, thermoanalytical and molar conductance measurements. In addition, the structure of the complex 5 has been determined by X-ray diffraction method. All ligands and metal complexes were tested as inhibitors of human leukemia (HL-60) cells growth and antibacterial and antifungal activities.

Cuvinte-cheie
Antileukemia, Antimicrobial activity, copper, nickel, Thiosemicarbazones, zinc complexes

Cerif XML Export

<?xml version='1.0' encoding='utf-8'?>
<CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'>
<cfResPubl>
<cfResPublId>ibn-ResPubl-187372</cfResPublId>
<cfResPublDate>2013-08-08</cfResPublDate>
<cfStartPage>8812</cfStartPage>
<cfURI>https://ibn.idsi.md/ro/vizualizare_articol/187372</cfURI>
<cfTitle cfLangCode='EN' cfTrans='o'>Synthesis and characterization of some new Cu(II), Ni(II) and Zn(II) complexes with salicylidene thiosemicarbazones: Antibacterial, antifungal and in vitro antileukemia activity</cfTitle>
<cfKeyw cfLangCode='EN' cfTrans='o'>Antileukemia; Antimicrobial activity; copper; nickel; Thiosemicarbazones; zinc complexes</cfKeyw>
<cfAbstr cfLangCode='EN' cfTrans='o'><p>Thirty two new Cu(II), Ni(II) and Zn(II) complexes (1-32) with salicylidene thiosemicarbazones (H<sub>2</sub>L<sup>1</sup>-H<sub>2</sub>L<sup>10</sup>) were synthesized. Salicylidene thiosemicarbazones, of general formula (X)N-NH-C(S)-NH(Y), were prepared through the condensation reaction of 2-hydroxybenzaldehyde and its derivatives (X) with thiosemicarbazide or 4-phenylthiosemicarbazide (Y = H, C<sub>6</sub>H<sub>5</sub>). The characterization of the new formed compounds was done by&nbsp;<sup>1</sup>H-NMR,&nbsp;<sup>13</sup>C-NMR, IR spectroscopy, elemental analysis, magnetochemical, thermoanalytical and molar conductance measurements. In addition, the structure of the complex 5 has been determined by X-ray diffraction method. All ligands and metal complexes were tested as inhibitors of human leukemia (HL-60) cells growth and antibacterial and antifungal activities.</p></cfAbstr>
<cfResPubl_Class>
<cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfResPubl_Class>
<cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId>
<cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
</cfResPubl_Class>
<cfPers_ResPubl>
<cfPersId>ibn-person-21973</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-21098</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-499</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-15307</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-12188</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfPers_ResPubl>
<cfPersId>ibn-person-21190</cfPersId>
<cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId>
<cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
</cfPers_ResPubl>
<cfFedId>
<cfFedIdId>ibn-doi-187372</cfFedIdId>
<cfFedId>10.3390/molecules18088812</cfFedId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
<cfFedId_Class>
<cfClassId>31d222b4-11e0-434b-b5ae-088119c51189</cfClassId>
<cfClassSchemeId>bccb3266-689d-4740-a039-c96594b4d916</cfClassSchemeId>
</cfFedId_Class>
<cfFedId_Srv>
<cfSrvId>5123451</cfSrvId>
<cfClassId>eda2b2e2-34c5-11e1-b86c-0800200c9a66</cfClassId>
<cfClassSchemeId>5a270628-f593-4ff4-a44a-95660c76e182</cfClassSchemeId>
</cfFedId_Srv>
</cfFedId>
</cfResPubl>
<cfPers>
<cfPersId>ibn-Pers-21973</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-21973-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
<cfFamilyNames>Pakhontsu</cfFamilyNames>
<cfFirstNames>E.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-21098</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-21098-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
<cfFamilyNames>Fala</cfFamilyNames>
<cfFirstNames>Valeriu</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-499</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-499-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
<cfFamilyNames>Gulya</cfFamilyNames>
<cfFirstNames>Aurelian</cfFirstNames>
<cfFamilyNames>Гуля</cfFamilyNames>
<cfFirstNames>Аурелиан</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-15307</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-15307-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
<cfFamilyNames>Poirier</cfFamilyNames>
<cfFirstNames>Donald</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-12188</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-12188-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
<cfFamilyNames>Tsapkov</cfFamilyNames>
<cfFirstNames>Victor I.</cfFirstNames>
<cfFamilyNames>Цапков</cfFamilyNames>
<cfFirstNames>Виктор</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfPers>
<cfPersId>ibn-Pers-21190</cfPersId>
<cfPersName_Pers>
<cfPersNameId>ibn-PersName-21190-3</cfPersNameId>
<cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId>
<cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId>
<cfStartDate>2013-08-08T24:00:00</cfStartDate>
<cfFamilyNames>Roshu</cfFamilyNames>
<cfFirstNames>T.</cfFirstNames>
</cfPersName_Pers>
</cfPers>
<cfSrv>
<cfSrvId>5123451</cfSrvId>
<cfName cfLangCode='en' cfTrans='o'>CrossRef DOI prefix service</cfName>
<cfDescr cfLangCode='en' cfTrans='o'>The service of issuing DOI prefixes to publishers</cfDescr>
<cfKeyw cfLangCode='en' cfTrans='o'>persistent identifier; Digital Object Identifier</cfKeyw>
</cfSrv>
</CERIF>